Theravance Biopharma reported cash of $326.5 million as of December 31, 2025, with no debt. The company expects approximately $400 million in cash at the end of the first quarter of 2026, including ...
The majority of agentic AI systems disclose nothing about what safety testing, and many systems have no documented way to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results